Tirzepatide is a once-weekly injectable that helps with weight loss by acting on two gut hormones, GIP and GLP-1, that quiet appetite, slow digestion, and steady blood sugar. In clinical trials, adults on the highest dose lost roughly a fifth of their body weight over about 17 months. For women, there is one detail that gets missed almost everywhere: tirzepatide can make oral birth control pills less reliable, so a backup method matters. Here is how the medication works, what the research actually shows, and how to start safely.
Key takeaways
- Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is the active ingredient in the brand drugs Zepbound (FDA-approved for chronic weight management) and Mounjaro (FDA-approved for type 2 diabetes; weight loss is an off-label use).
- In the SURMOUNT-1 trial, adults lost about 15% to 22.5% of body weight over 72 weeks, depending on dose. Individual results vary and depend on the full program, nutrition, activity, and dose.
- Women-specific must-know: tirzepatide can reduce the effectiveness of oral birth control pills. Use a backup barrier method or a non-oral method for 4 weeks after starting and after each dose increase.
- Safety: GLP-1-type medicines carry a boxed warning for thyroid C-cell tumors and cautions for pancreatitis, gallbladder issues, and strong stomach side effects. They are not for use in pregnancy. Talk to a licensed provider.
- At Elara, compounded tirzepatide starts at $355/month, all-inclusive. Compounded medications are not FDA-approved.
What is tirzepatide, and how does it work for weight loss?
Tirzepatide is a medication that mimics two natural gut hormones at once. That is what makes it different from semaglutide, which mimics only one.
Your gut releases hormones after you eat. Two of them, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), help control blood sugar and tell your brain you have had enough. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it switches on both signals. Semaglutide, by comparison, acts on the GLP-1 pathway alone.
In plain terms, tirzepatide does a few things at once:
- Lowers appetite and reduces "food noise," the constant background pull toward eating.
- Slows gastric emptying, so food stays in your stomach longer and you feel full sooner and for longer.
- Improves how your body handles blood sugar and insulin, which matters a lot for women with insulin resistance, such as many with PCOS.
You take it as a small once-weekly injection under the skin, and the dose is increased slowly over months to limit stomach side effects. The medication does the biological heavy lifting on appetite and satiety, but it works best paired with protein-forward nutrition and regular movement, not instead of them.
How much weight can women lose on tirzepatide?
In clinical trials, adults on tirzepatide lost a substantial share of their body weight, but the numbers describe trial averages, not a promise for any one person.
The main study is SURMOUNT-1, published in the New England Journal of Medicine in 2022. It followed adults with obesity (without diabetes) on once-weekly tirzepatide for 72 weeks, about 17 months. Average weight loss rose with the dose:
| Weekly tirzepatide dose | Average body-weight loss (SURMOUNT-1, 72 weeks) |
|---|---|
| 5 mg | ~15% |
| 10 mg | ~19.5% |
| 15 mg (highest) | ~21% to 22.5% |
| Placebo (for comparison) | ~2.4% |
These are averages from a controlled trial. Your result depends on your starting point, your dose, how your body responds, and the everyday work around the medication, food, protein, sleep, activity, and consistency. Weight loss is also not linear: most people see faster early changes, then a slower, steadier phase. A licensed provider helps set a realistic pace and adjusts the plan over time.
For a step-by-step look at how the dose builds from the starter amount to maintenance, see the tirzepatide dosage chart and titration guide.
Is tirzepatide better than semaglutide?
For average weight loss, the research points to tirzepatide edging out semaglutide, but "better" is personal, and depends on your body, your history, and your goals.
A JAMA Internal Medicine study compared more than 18,000 adults on the two medications in real-world practice (matched carefully so the groups were similar). At 12 months, people on tirzepatide had lost about 15.3% of their weight on-treatment, versus about 8.3% on semaglutide. More people on tirzepatide reached the bigger milestones, too, for example, about 42% hit at least 15% weight loss, versus about 18% on semaglutide. This lines up with what the separate trials suggest.
Here is a fair, plain-English comparison:
| Tirzepatide | Semaglutide | |
|---|---|---|
| How it works | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Brand names | Zepbound (weight), Mounjaro (diabetes) | Wegovy (weight), Ozempic (diabetes) |
| Average trial weight loss | ~15-22.5% (SURMOUNT-1, 72 wks) | ~15% (STEP 1, 68 wks) |
| Birth control pill note | Can reduce pill effectiveness, use backup | No such warning found in studies |
| Typical cost | Higher (roughly 2-3× semaglutide) | Lower |
| At Elara (compounded) | From $355/month, all-in | From $247/month, all-in |
Bigger average numbers do not automatically make tirzepatide the right pick for you. Some women tolerate one better than the other, cost is a real factor, and, as covered below, the birth-control interaction differs between the two. If you are weighing them for a specific reason like PCOS, read the deeper dive on tirzepatide vs semaglutide for PCOS, and see our full semaglutide for women guide for the other side of the comparison. The best choice is one you make with a licensed provider.
What should women know before starting tirzepatide?
Most of the weight-loss coverage is written for a general audience. A few things matter specifically for women, and one of them is genuinely important.
Tirzepatide can make birth control pills less reliable
This is the detail that too many people miss. Because tirzepatide slows gastric emptying, it can lower how much of an oral contraceptive pill your body absorbs, which can make the pill less effective. The Zepbound and Mounjaro FDA labels advise women using birth control pills to either switch to a non-oral method or add a barrier method (like condoms) for 4 weeks after starting, and for 4 weeks after each dose increase.
Methods that are not absorbed through the stomach are not affected in the same way, for example, an IUD, an implant, the injection, the vaginal ring, or the patch. Semaglutide does not carry this warning. If you are on the pill, this is worth a direct conversation before you start. We cover it in full in tirzepatide and birth control.
PCOS and insulin resistance
Many women exploring tirzepatide have PCOS, where insulin resistance and weight are tightly linked. GLP-1-type medicines can help with weight and blood-sugar handling in PCOS, though no tirzepatide product is FDA-approved specifically for PCOS, that use is off-label and belongs with a clinician. For the evidence and how the two molecules compare for this, see tirzepatide vs semaglutide for PCOS.
Pregnancy and trying to conceive
Tirzepatide is not recommended during pregnancy or breastfeeding, and it is not a fertility drug. Because weight loss and better insulin sensitivity can restart ovulation, some women become more fertile than they expect, which, combined with the pill interaction above, is exactly why backup contraception matters. If you are planning a pregnancy, talk with your provider about when to stop.
Protecting muscle and your face
Fast weight loss of any kind can cost lean muscle along with fat, and women, especially in perimenopause and menopause, are more vulnerable to losing muscle and facial fullness. The protective moves are not restrictive: prioritize protein, add resistance training a couple of times a week, and do not under-eat. Route these questions to your provider as your dose builds.
What are the risks and side effects of tirzepatide?
The most common side effects are stomach-related, and there are a few serious risks every patient should understand before starting.
The most common side effects reported in studies (in at least 5% of patients) are nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, and burping, per the FDA prescribing information. These tend to be worst when you first start or step up a dose, and slow titration is designed to ease them.
Serious risks and cautions include:
- Thyroid C-cell tumor boxed warning. In animal studies, tirzepatide caused thyroid C-cell tumors; it is not known whether this applies to humans. Tirzepatide is contraindicated if you or a close family member has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider about any personal or family thyroid history.
- Pancreatitis (inflammation of the pancreas), seek care for severe, persistent stomach pain.
- Gallbladder problems, including gallstones.
- Low blood sugar (hypoglycemia), especially if combined with insulin or a sulfonylurea.
- Dehydration from vomiting or diarrhea, which can affect the kidneys.
This is not the full list. Read the complete FDA prescribing information for Zepbound or Mounjaro, and talk to a licensed provider about whether tirzepatide is appropriate for you.
Brand vs compounded tirzepatide: what the names actually mean
Tirzepatide comes as FDA-approved brand-name drugs and as compounded preparations. The distinction is important, and the wording is not the same as "generic."
The brand-name products:
- Zepbound is FDA-approved for chronic weight management in eligible adults.
- Mounjaro is FDA-approved for type 2 diabetes. Using it for weight loss is off-label, a legal, common practice, but not an FDA-approved use for that purpose.
Compounded tirzepatide is prepared by a state-licensed compounding pharmacy and prescribed by a licensed clinician when it is appropriate for an individual patient. It is not a "generic" version of Zepbound or Mounjaro, and it is not the same as the branded finished product. Most importantly:
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.
Where compounding stands in 2026
The regulatory picture has changed, and the old "shortage" storyline is out of date. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and it has clarified that broad shortage-based compounding of "essentially copies" has wound down. Narrow, patient-specific compounding under section 503A continues where a licensed clinician documents a specific clinical need for an individual patient.
Looking ahead, on April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B "bulks" list used by larger outsourcing facilities; the public comment period was extended to July 30, 2026. This is a proposal, not a final rule, and it is subject to change. Regulators are also watching this space closely, in December 2025 the FTC finalized an order against a telehealth GLP-1 seller over deceptive advertising and hidden costs. We keep our program aligned with these rules and update our patients as things evolve.
How Elara helps
Elara is a women's telehealth program built around GLP-1 weight care, with tirzepatide as a core option, offered honestly, with a licensed provider reviewing every patient.
Here is how it works:
- You start with a quick eligibility check, then a licensed provider reviews your history, including your goals, medical background, birth control, and pregnancy plans. Depending on your state and case, that review is synchronous or asynchronous.
- If tirzepatide is appropriate for you, you can choose branded Zepbound or Mounjaro, or compounded tirzepatide from a state-licensed pharmacy. Branded pricing at Elara: listed on each medication page and finalized at checkout.
- The price is all-inclusive and cash-pay, no insurance hurdles, no denials, no surprise fees. One price covers the provider visit, the medication, shipping, and ongoing access to the medical team, the private community, the Elara app, recipes, and workouts.
Elara's compounded tirzepatide pricing:
| Plan | Total price | ≈ per month |
|---|---|---|
| Monthly | $355 | $355/mo |
| Quarterly (3 mo) | $890 | $297/mo |
| 6-month | $1,790 | $298/mo |
| 12-month | $3,580 | $298/mo |
For context on how that compares to brand-name pricing: brand Zepbound lists around $1,086 per month (Lilly offers lower self-pay single-dose vials, roughly $299-$449/month, verify current pricing), and brand Wegovy (semaglutide) lists around $1,349 per month through NovoCare. Elara's compounded tirzepatide is a different thing from the branded finished drug, priced on access, not "the same medication for less." A full breakdown lives in our tirzepatide cost guide. Elara serves all 50 states plus Puerto Rico, with 7-day-a-week human support.
See Elara's compounded tirzepatide plans, from $355/month, all-in (medication, provider visit, and shipping included). A licensed provider reviews every patient. Compounded medications are not FDA-approved. Start with our free eligibility check.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.
Frequently asked questions
How does tirzepatide work for weight loss?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It reduces appetite, slows how fast your stomach empties so you feel full longer, and improves how your body handles blood sugar and insulin. Taken as a weekly injection alongside good nutrition and activity, that combination makes it easier to eat less without constant hunger.
Is tirzepatide better than semaglutide?
For average weight loss, research favors tirzepatide. In a JAMA Internal Medicine study of over 18,000 adults, 12-month weight loss was about 15.3% on tirzepatide versus 8.3% on semaglutide. But "better" is individual, side effects, cost, medical history, and the birth-control interaction all matter. A licensed provider can help you choose.
How much does tirzepatide cost at Elara?
Elara's compounded tirzepatide starts at $355/month on the monthly plan and drops to about $298/month on the 12-month plan. The price is all-inclusive, provider visit, medication, shipping, and ongoing support, and cash-pay, with no insurance needed. Branded Zepbound and Mounjaro are also available; compounded medications are not FDA-approved.
Does tirzepatide affect birth control?
Yes, it can make oral birth control pills less effective, because it slows stomach emptying and lowers pill absorption. The FDA labels advise switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase. Non-oral methods like the IUD, implant, injection, ring, and patch are not affected the same way.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved and is not reviewed by the FDA for safety, effectiveness, or quality. It is prepared by a state-licensed compounding pharmacy and prescribed by a licensed clinician for an individual patient when appropriate. The FDA-approved brand-name tirzepatide products are Zepbound (for weight management) and Mounjaro (for type 2 diabetes).
How do I start tirzepatide with Elara?
Begin with a free online eligibility check, then a licensed provider reviews your history and goals, including birth control and pregnancy plans. If tirzepatide is appropriate for you, your prescription is filled and shipped to your door, and you get ongoing access to the medical team and the Elara app. A licensed provider reviews every patient.
The bottom line
Tirzepatide is a twice-acting (GIP and GLP-1) weekly injection with strong trial results, roughly 15% to 22.5% average weight loss over 72 weeks, and an edge over semaglutide in head-to-head data. For women, the non-negotiable detail is the birth-control interaction, plus the standard GLP-1 safety picture, including the thyroid C-cell boxed warning. Whether branded or compounded, it should be prescribed and monitored by a licensed provider who knows your history.
References
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity." JAMA Internal Medicine. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080
- Zepbound (tirzepatide) Prescribing Information, DailyMed (U.S. National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Mounjaro (tirzepatide) Prescribing Information, DailyMed (U.S. National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- Wegovy list price, NovoCare. https://www.novocare.com/patient/medicines/wegovy.html
- "Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients." Pharmaceutical Executive. https://www.pharmexec.com/view/lilly-reduces-price-of-zepbound-single-dose-vials-for-self-pay-patients
- "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." U.S. Food and Drug Administration, April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize." U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- "FTC Approves Final Order against Telehealth Provider NextMed." Federal Trade Commission, December 2025. https://www.ftc.gov/news-events/news/press-releases/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-over-charges-it-used-deceptive
This article is for general education and is not medical advice. Talk to a licensed clinician about your situation.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.